Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

Patients' expression of CEACAM5 might hold the key to activity after all.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.